Figure 2From: Alendronate increases BMD at appendicular and axial skeletons in patients with established osteoporosisPercentage changes of Bone Alkaline Phosphate (BALP) and Deoxypyridoline (DPD) level after 12-month treatment compared between Alendronate (ALN) and placebo control group (CON) (Data are in mean ± SE). *: p < 0.05; **: p < 0.01.Back to article page